Thomas E. Shenk To Retire From Merck’s Board of Directors
February 8, 2012 3:00 pm ET
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Thomas E. Shenk, Ph.D., has decided to retire from
its board of directors, effective today. Dr. Shenk is leaving the board
to focus on the new company he is forming to commercialize discoveries
made in his Princeton University laboratory in the area of antiviral
therapeutics.
Dr. Shenk has been Elkins Professor in the Department of Molecular
Biology at Princeton University since 1984. He served as the
department’s chairman from 1996 to 2004. Dr. Shenk joined Merck’s board
in 2001.
About Merck
Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter, Facebook and YouTube.
Merck
Media:
Ron Rogers, 908-423-6449
or
Investors:
Carol Ferguson, 908-423-4465
